AR126778A1 - Compuestos deuterados - Google Patents
Compuestos deuteradosInfo
- Publication number
- AR126778A1 AR126778A1 ARP220102177A ARP220102177A AR126778A1 AR 126778 A1 AR126778 A1 AR 126778A1 AR P220102177 A ARP220102177 A AR P220102177A AR P220102177 A ARP220102177 A AR P220102177A AR 126778 A1 AR126778 A1 AR 126778A1
- Authority
- AR
- Argentina
- Prior art keywords
- twenty
- ppara
- pparg
- disease
- deuterated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101150014691 PPARA gene Proteins 0.000 abstract 3
- 101150023417 PPARG gene Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229940125542 dual agonist Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010061481 Renal injury Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical class C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000037806 kidney injury Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021112521 | 2021-08-13 | ||
| CN2022106648 | 2022-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126778A1 true AR126778A1 (es) | 2023-11-15 |
Family
ID=85199822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102177A AR126778A1 (es) | 2021-08-13 | 2022-08-12 | Compuestos deuterados |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240270731A1 (https=) |
| EP (1) | EP4384507A4 (https=) |
| JP (1) | JP2024532807A (https=) |
| KR (1) | KR20240047401A (https=) |
| CN (1) | CN116848095B (https=) |
| AR (1) | AR126778A1 (https=) |
| CA (1) | CA3227149A1 (https=) |
| IL (1) | IL310176A (https=) |
| MX (1) | MX2024001889A (https=) |
| TW (1) | TW202320762A (https=) |
| WO (1) | WO2023016440A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118480034B (zh) * | 2023-02-13 | 2025-02-11 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60211891T2 (de) * | 2001-05-15 | 2007-05-24 | F. Hoffmann-La Roche Ag | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| CN109265380A (zh) * | 2017-10-18 | 2019-01-25 | 深圳市塔吉瑞生物医药有限公司 | 取代的丙-2-烯-1-酮化合物及其药物组合物 |
| WO2020156683A1 (en) * | 2019-02-01 | 2020-08-06 | F. Hoffmann-La Roche Ag | Aleglitazar for use in the treatment or prevention of major adverse cardiac events |
| CN112209896B (zh) * | 2019-07-10 | 2023-05-16 | 苏州泽璟生物制药股份有限公司 | 噻唑烷二酮衍生物以及包含其的药物组合物 |
| CN118480034B (zh) * | 2023-02-13 | 2025-02-11 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
-
2022
- 2022-08-09 TW TW111129796A patent/TW202320762A/zh unknown
- 2022-08-09 JP JP2024508768A patent/JP2024532807A/ja active Pending
- 2022-08-09 EP EP22855421.8A patent/EP4384507A4/en active Pending
- 2022-08-09 CA CA3227149A patent/CA3227149A1/en active Pending
- 2022-08-09 CN CN202280014488.6A patent/CN116848095B/zh active Active
- 2022-08-09 US US18/293,337 patent/US20240270731A1/en active Pending
- 2022-08-09 MX MX2024001889A patent/MX2024001889A/es unknown
- 2022-08-09 IL IL310176A patent/IL310176A/en unknown
- 2022-08-09 WO PCT/CN2022/111089 patent/WO2023016440A1/en not_active Ceased
- 2022-08-09 KR KR1020247007871A patent/KR20240047401A/ko active Pending
- 2022-08-12 AR ARP220102177A patent/AR126778A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202320762A (zh) | 2023-06-01 |
| CA3227149A1 (en) | 2023-02-16 |
| US20240270731A1 (en) | 2024-08-15 |
| EP4384507A4 (en) | 2025-06-18 |
| CN116848095A (zh) | 2023-10-03 |
| EP4384507A1 (en) | 2024-06-19 |
| JP2024532807A (ja) | 2024-09-10 |
| WO2023016440A1 (en) | 2023-02-16 |
| AU2022327461A1 (en) | 2024-02-01 |
| KR20240047401A (ko) | 2024-04-12 |
| CN116848095B (zh) | 2024-05-24 |
| MX2024001889A (es) | 2024-02-29 |
| IL310176A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126778A1 (es) | Compuestos deuterados | |
| AR107360A1 (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| AR124672A2 (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR097403A1 (es) | Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación | |
| AR127404A1 (es) | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos | |
| AR089120A1 (es) | Compuestos herbicidas | |
| Joshi et al. | Functional diversity of the excretory/secretory proteins of nematode parasites | |
| MX380999B (es) | Compuestos derivados de alquilos heterocíclicos como inhibidores de histona desacetilasa selectivos y composiciones farmacéuticas que los comprenden. | |
| PE20221152A1 (es) | Inhibidores del factor d del complemento para administracion oral | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| Giustina et al. | Lipoic acid and fish oil combination potentiates neuroinflammation and oxidative stress regulation and prevents cognitive decline of rats after sepsis | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| KR20180050434A (ko) | 구충제로서의 신규 술포닐아미노벤즈아미드 화합물 | |
| WO2018064953A1 (zh) | Idhp在制备预防和治疗冠状动脉粥样硬化疾病药物或保健品中的应用 | |
| RU2739915C2 (ru) | Соединение, имеющее действие ингибирования агрегации тромбоцитов, и его соль, и содержащая такие соединения композиция для предупреждения или лечения тромботических заболеваний | |
| JPWO2019131897A1 (ja) | 白内障の予防剤および／または治療剤、白内障の予防および／または治療のための医薬組成物、これらを製造するためのｐｐａｒ活性化剤の使用、ならびに点眼剤 | |
| AR106295A1 (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo | |
| AR092088A1 (es) | Compuestos de pirazol-carboxamida, composiciones y metodos de uso | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| TWI867308B (zh) | 治療和/或預防由ｎｌｒｐ３介導的疾病和病症的苯並咪唑衍生物 | |
| AR087822A1 (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmaceuticos | |
| ECSP23019518A (es) | Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias | |
| Collins et al. | Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. |